Abstract:Background The imbalance of T help 17 cells (Th17)/regulatory T cells (Tregs) is considered to be a pivotal cause of autoimmune diseases1, including systemic lupus erythematosus (SLE). However, previous reports1,2 describing the respective changes of Tregs and Th17 cells in SLE patients were controversial because a few samples or diverse markers were used to identify Tregs with little consensus. Objectives To clarify the status of Tregs and Th17 in SLE, we investigated the frequencies of Tregs and Th17 cells on a large scale and whether those defects can be corrected by the supplementation of low-dose human recombinant interleukin-2 (IL-2). Methods Two hundred and thirty-five SLE patients (219 women and 16 men), with mean age of 37.80±14.00 years, were enrolled. The disease activity using European League Against Rheumatism (EULAR) criteria was judged for SLE patients with erythrocyte sedimentation rate (ESR) and SLEDAI scores. The frequencies of CD3+CD4+FOXP3+Treg cells and Th17 cells in peripheral blood from these patients were measured by flow cytometry. And low-dose IL-2 was used among 127 patients at a dosage of fifty WIU every day for five days. Immunological and clinical assessments were performed again at the end of IL-2 treatment. Ninety healthy volunteers, matched for patients9 age and gender, were also included for the estimation of CD4+ T cell subsets. Results As compared to healthy controls (median of Treg cells: 33.09 cells/ul), the frequencies of circulating CD4+CD25+FOXP3+Treg cells were significantly decreased in SLE patients (median: 15.49 cells/ul, P<0.001). The median ratios of Th17/Tregs cells in patients were greatly higher than those of healthy volunteers [0.42 (0.19, 0.88) vs. 0.21 (0.15, 0.34), P<0.001]. There was not significantly different in circulating Th17 cell between two groups. Moreover, CD4+CD25+FOXP3+Treg cells were negatively correlated with ESR and SLEDAI score (r=-0.198, P=0.01; r=-0.25, P=0.002).While no obvious correlation was seen between Th17 cells and SLEDAI score. After IL-2 therapy in SLE, there was a four-fold increase in circulating CD4+CD25+FOXP3+Treg cells [43.73 (24.08,74.22) vs. 11.95 (7.51,20.34),P<0.001], whereas Th17 cells were increased slightly. The ratio of Th17/Tregs was decreased significantly in patients with IL-2 treatment [0.19 (0.09,0.41) vs. 0.52 (0.23,0.95),P<0.001], tended to balance and had no difference with healthy individual (P=0.275). Conclusions With the increase of disease activity,CD4+CD25+FOXP3+Treg cells were gradually reducing, while Th17 cells did not show a significant change, indicating that the reduction of Tregs but not the elevation of Th17 cells may be the major reason for imbalance of Th17/Tregs. It is speculated that SLE is an autoimmune disease triggered by the defect of immunotolerance. More importantly, low-dose IL-2 selectively modulated the abundance of Tregs, which effectively induced autoimmune tolerance and further improved clinical symptoms. References Ji Y, Xue Y, Hejian Z, et al.Recovery of the immune balance betweenTh17 and regulatory T cells as a treatment for systemic lupus erythematosus[J]. Rheumatology 2011;50:1366–1372. Steinmetz OM, Turner JE, Paust HJ et al. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis[J]. J Immunol 2009;183:4693–704. Disclosure of Interest None declared

Increased IL-10/IL-17 Ratio is Aggravated along with the Prognosis of Patients with Chronic Lymphocytic Leukemia

[Ratio Balance of Th17 and Treg Cells in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia].

Increased frequencies of Th17 in the peripheral blood of patients with chronic lymphocytic leukemia: A one year follow-up.

Increased Serum Level of Interleukin-10 Predicts Poor Survival and Early Recurrence in Patients With Peripheral T-Cell Lymphomas

Treg/Th17 imbalance in malignant pleural effusion partially predicts poor prognosis.

Study on the value of Foxp3 + Tregs level in peripheral blood of patients with relapsed and refractory acute lymphoblastic leukemia after CAR-T cell therapy

Increased Frequency of Circulating Activated FOXP3+ Regulatory T Cell Subset in Patients with Chronic Lymphocytic Leukemia Is Associated with the Estimate of the Size of the Tumor Mass, STAT5 Signaling and Disease Course during Follow-Up of Patients on Therapy

Exploring the prognostic value of T follicular helper cell levels in chronic lymphocytic leukemia

Long-term Prognostic Significance of Interleukin-17-producing T Cells in Patients with Non-Small Cell Lung Cancer

IL-10 Induces the Development of Immunosuppressive CD14 + HLA-DR Low/− Monocytes in B-cell Non-Hodgkin Lymphoma

Relationship between Treg and Th17 cells in peripheral blood of acute leukemia patients

Characterization of Regulatory T Cells in Patients with B-cell Chronic Lymphocytic Leukemia.

Relationship Of Regulatory T Cell Level In Peripheral Blood With Curative Efficacy And Prognosis Of Patients With Non-Hodgkin'S Lymphoma

Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis.

Decreased Breg/Th17 Ratio Improved the Prognosis of Patients with Ulcerative Colitis

OP0043 the Number of Circulating Regulatory T Cells is Reduced and Low-Dose Il-2 Selectively Stimulates Its Proliferation in Patients with Systemic Lupus Erythematosus

The Relationship Between Reducing of Peripheral Blood Treg in Primary Diffuse Large B-Cell Lymphoma Patients and Poor Prognosis

Effect of T-regulatory cells and interleukin-35, interleukin-10, and transforming growth factor-beta on diffuse large B-cell lymphoma

Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes

BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion

Increased Autocrine Interleukin‐6 Production is Significantly Associated with Worse Clinical Outcome in Patients with Chronic Lymphocytic Leukemia